Lexeo director granted 50,000 stock options at $5.81
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino received a grant of stock options covering 50,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $5.81 per share and expire on April 27, 2036. They vest in equal annual installments over three years, so the award becomes fully exercisable on the third anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds options for 50,000 underlying shares directly.
Insider Trade Summary
Grant/Award: 50,000 shares
Grant/Award
1 txn
Insider
Sepp-Lorenzino Laura
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 50,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 50,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service.
Key Figures
Options granted: 50,000 options
Exercise price: $5.81 per share
Expiration date: April 27, 2036
+3 more
6 metrics
Options granted
50,000 options
Stock Option (right to buy) grant on April 28, 2026
Exercise price
$5.81 per share
Conversion or exercise price for the options
Expiration date
April 27, 2036
Option expiration for the 50,000-share grant
Underlying shares
50,000 shares
Common stock underlying the stock options
Post-grant holdings
50,000 options
Total derivative securities following transaction
Vesting schedule
3 annual installments
Fully vested on third anniversary of grant date
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 5.8100"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shall vest and become exercisable in equal annual installments over a three year period"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-04-27T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Lexeo Therapeutics (LXEO) disclose in this Form 4?
Lexeo Therapeutics reported a stock option grant to director Laura Sepp-Lorenzino for 50,000 shares of common stock. The options are a compensation-related award with a $5.81 exercise price and a long-term expiration date in 2036, aligning incentives with shareholders.
How many Lexeo Therapeutics (LXEO) options were granted to Laura Sepp-Lorenzino?
She was granted stock options over 50,000 shares of Lexeo Therapeutics common stock. These options vest in three equal annual installments and become fully exercisable on the third anniversary of the grant date, assuming she continues to serve the company during that period.
What is the exercise price and expiration date of the LXEO options?
The granted stock options have an exercise price of $5.81 per share and expire on April 27, 2036. This gives the director a long window to potentially exercise the options if Lexeo Therapeutics’ share price exceeds the $5.81 strike price in the future.
How do the Lexeo Therapeutics (LXEO) options vest for the director?
The options vest in equal annual installments over three years, fully vesting on the third anniversary of the grant date. Vesting is contingent on Laura Sepp-Lorenzino’s continuous service with Lexeo Therapeutics, encouraging ongoing board engagement and longer-term alignment with shareholders.
Is this Form 4 transaction a market purchase or a grant for LXEO?
This Form 4 reflects a compensation-related grant, not an open-market purchase or sale. The transaction code is “A” for an award, indicating Lexeo Therapeutics granted 50,000 stock options to the director at a $5.81 exercise price with structured vesting and a 2036 expiration.
What is Laura Sepp-Lorenzino’s position after this Lexeo Therapeutics grant?
Following the grant, she directly holds stock options covering 50,000 shares of Lexeo Therapeutics common stock. These options will become exercisable over three years, subject to her continued service, potentially increasing her economic exposure to the company’s equity over time.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates